What is Longevity Tech — The Paradigm Shift of "Treating Aging"
Longevity Tech refers to a suite of technologies that treat aging itself as an interventable biological process, with the goal of extending healthy lifespan.
Conventional medicine has addressed the *results* of aging — cancer, heart disease, Alzheimer's — on a case-by-case basis. Longevity Tech flips this paradigm, targeting the *causes* of aging directly. The "12 Hallmarks of Aging" by López-Otín et al., updated in *Cell* in 2023, systematizes 12 biological mechanisms that drive aging — including genomic instability, telomere shortening, epigenetic alterations, cellular senescence, stem cell exhaustion, and chronic inflammation. Each of these mechanisms represents a potential therapeutic target.
The distinction between healthspan and lifespan is critical. According to the WHO, Japanese people enjoy an average of 75 healthy, disability-free years (among the highest in the world), yet there remains a gap of roughly 9 years before average total lifespan. Longevity Tech aims to close this gap and ultimately extend healthspan dramatically.
The divergence between biological age and chronological age is another core concept. Epigenetic clocks measured via DNA methylation patterns — such as the Horvath Clock, GrimAge, and DunedinPACE — now make it possible to quantify the body's "true age." TruDiagnostic measures over 100,000 DNA markers and determines biological age using peer-reviewed algorithms.
Why is this field growing explosively right now? In his October 2024 essay "Machines of Loving Grace," Anthropic CEO Dario Amodei predicted that "AI will accelerate biological research by more than tenfold, compressing into 5–10 years the progress that human biologists would take 50–100 years to achieve," and touched on the possibility of doubling human lifespan. The convergence of AI, genomics, and biotechnology — combined with massive investment from billionaires — has propelled Longevity Tech from "science fiction" to "investment thesis."
Market Size — 2024 VC Investment Amount Up 220% Year-over-Year
The numbers confirm the rapid expansion of the longevity tech market.
The overall longevity market is projected to reach approximately $29.8 billion in 2025, while the longevity biotech market is expected to grow from approximately $9.9 billion in 2026 to approximately $29.3 billion in 2035 (CAGR 12.84%, Mordor Intelligence). A broader estimate from Market Research Future puts the figure at over $63 billion by 2035. The longevity economy in its widest definition is projected to reach $27 trillion by 2030 (Oxford Economics).
VC investment activity has been dramatic. From $421 million in 2023, investment surged to $8.49 billion in 2024 — a 220% year-over-year increase across 325 deals. The average deal size jumped from $20 million in 2023 to $69 million in 2025. Cell reprogramming companies have raised over $4.5 billion in four years, accounting for approximately 60% of all longevity VC funding.
Major pharmaceutical companies are also accelerating their entry into the space. Eli Lilly has invested in NewLimit, and Nature Biotechnology published a paper titled "Is GLP-1 the first longevity drug?" Novo Nordisk announced that GLP-1 could become a longevity drug. Meanwhile, AbbVie ended its 11-year partnership with Calico (an Alphabet subsidiary) in November 2025, signaling a clear strategic shift away from small-molecule drugs toward injectable therapies and gene therapy.
Cellular Reprogramming — The Biggest Investment Theme
The largest investment theme in longevity tech is cellular reprogramming, based on the discoveries of Nobel laureate Shinya Yamanaka. Approximately 60% of all longevity VC funding is concentrated in this field.
Altos Labs (founded in 2022) is backed by Jeff Bezos and others with $3 billion (approximately ¥450 billion) — one of the largest biotech launch funding rounds in history. The company has recruited Juan Carlos Izpisua Belmonte, Jennifer Doudna (Nobel laureate for CRISPR), and Shinya Yamanaka as scientific advisors, and researches "partial reprogramming" — a technique that rejuvenates cells using short pulses of Yamanaka factors while reducing tumor risk. In 2025, they published a paper on "mesenchymal drift" in *Cell*, demonstrating that perfusing aged donor kidneys with Yamanaka factor pulses in mice significantly improved post-transplant survival rates. Ex vivo organ reprogramming may become the first clinical application.
Retro Biosciences received a personal investment of $180 million (approximately ¥27 billion) from Sam Altman and is raising a $1 billion Series A at a $5 billion valuation. The company has three pillars — cellular reprogramming, autophagy, and plasma factors — and in 2025 initiated a Phase I trial of RTR242 (a small molecule that restores lysosomal function) in Australia. In a joint research effort with OpenAI, AI-designed transcription factors improved reprogramming efficiency by 50-fold. The goal is to extend healthspan by 10 years.
NewLimit, co-founded by Brian Armstrong (Coinbase CEO), raised a $130 million Series B led by Kleiner Perkins in 2025, followed five months later by an additional $45 million from Eli Lilly, bringing the valuation to $1.62 billion (approximately ¥243 billion). The company demonstrated that eight new transcription factor sets in hepatocytes and fourteen in T cells restore rejuvenation function. Eli Lilly's involvement signals that major pharmaceutical companies have become convinced that "cellular aging intervention" is a new therapeutic category.
Turn Biotechnologies is developing mRNA-based epigenetic reprogramming (ERA technology) and plans to begin clinical trials for a skin rejuvenation treatment in 2026. Rejuvenate Bio (a spinout from George Church's lab) delivers OSK factors via AAV-mediated gene therapy and has demonstrated lifespan extension and epigenetic age reversal in normal mice — the first published study to show lifespan extension in normal mice through epigenetic reprogramming.
Senolytics and GLP-1 — Clinically Proven Effects
If cellular reprogramming is a "technology of the future," senolytics and GLP-1 are approaches that already have clinical data today.
Senolytics (drugs that eliminate aged "zombie cells") have approximately 20 clinical trials underway. A December 2024 pilot trial of dasatinib + quercetin significantly improved cognitive function in elderly patients with mild cognitive impairment. Unity Biotechnology (NASDAQ: UBX)'s UBX1325 missed its primary endpoint in a Phase 2b trial for diabetic macular edema, but showed results exceeding aflibercept in a moderate-severity subgroup. Under Cambrian Biopharma, four assets are currently in clinical trials.
The longevity implications of GLP-1 agonists (semaglutide/Ozempic) have sent shockwaves through the industry. In a 32-week double-blind, placebo-controlled trial, semaglutide reversed biological age by an average of 3.1 years, slowed the pace of aging by approximately 9%, and demonstrated organ-specific rejuvenation. A Nature Medicine report (late 2025) found that semaglutide and tirzepatide reduced the risk of myocardial infarction, stroke, and all-cause mortality. However, the above trial was conducted in an HIV-positive population, and effects in healthy individuals remain unconfirmed — the leading interpretation is that these drugs are "most effective in populations with high inflammatory burden."
The Revolution That Starts with Dogs——Loyal LOY-002
Surprisingly, the longevity tech company making the fastest progress toward regulatory milestones is working on a lifespan-extension drug for dogs.
Loyal's LOY-002 is a caloric restriction mimetic for large dogs, and 2 of the 3 major technical sections (efficacy + safety) have already been approved in its FDA conditional approval application. Only manufacturing approval remains. The STAY trial has completed enrollment of 1,300 dogs across 70 veterinary clinics. If approved, it would be the first FDA-approved lifespan-extension drug in any species, with a target market launch in 2026. Success in dogs could set a regulatory pathway precedent for human anti-aging therapeutics.
Biomarkers and Diagnostics — Technology for "Measuring Aging"
To treat aging, we must first quantify it.
Epigenetic clocks calculate biological age from DNA methylation patterns. The Horvath Clock (developed by UCLA Professor Steve Horvath) was the pioneer, with GrimAge and PhenoAge emerging as second- and third-generation versions that integrate markers associated with mortality risk and organ performance. DunedinPACE measures "the speed of aging at this very moment" and was the only measure in the CALERIE study to demonstrate both predictive power for health improvement and responsiveness to short-term changes.
Consumer-facing products are also growing. Tally Health (co-founded by David Sinclair) analyzes approximately 850,000 DNA methylation sites from a cheek swab to deliver personalized longevity plans. InsideTracker calculates biological age using blood biomarkers and machine learning. GlycanAge offers a glycan-based biological age test that predicts chronological age with a margin of error of 9.7 years.
Silicon Valley VC Perspective — Entering the "Conviction" Phase
Silicon Valley VCs view longevity tech as having shifted from a phase of "exploration" to one of "conviction."
Khosla Ventures is the most active institutional investor, having participated in at least 10 longevity deals between 2022 and 2025 (including NewLimit, Rubedo Life Sciences, Rejuvenation Technologies, and Viome). Kleiner Perkins led NewLimit's Series B ($130M). a16z Bio has invested in Levels, Thorne HealthTech, and Function Health ($53M Series A). Founders Fund (Peter Thiel) has also backed NewLimit and others.
Developments in the Middle East are also worth noting. Saudi Arabia's Hevolution Foundation has a budget of up to $1 billion per year and has provided over $400M in research grants to more than 200 global laboratories. Its largest commitment in 2025 was $230M. As part of Vision 2030, Saudi Arabia has set a target average lifespan of 80 years and hosted the Global Healthspan Summit 2025 in Riyadh, drawing over 2,000 attendees. The UAE's longevity sector is projected to reach $23 billion by 2026, with two longevity-focused R&D facilities currently under construction.
Peter Diamandis's XPRIZE Healthspan is a $101M (approximately ¥15.15 billion) seven-year competition, and BOLD Capital Partners has deployed over $600M into longevity startups.
Notable Figures' Views — From Billionaires to Nobel Laureates
The most influential figures in the tech industry are making their names in longevity tech.
Jeff Bezos has invested in Altos Labs ($3 billion) and Unity Biotechnology. Sam Altman personally invested $180 million in Retro Biosciences, positioning it as "if OpenAI changes the world with AI, Retro will change the world with aging." Brian Armstrong co-founded NewLimit and brought Eli Lilly on board. Peter Thiel donated $7 million to the Methuselah Foundation and has invested in numerous longevity companies through Founders Fund.
Bryan Johnson uses himself as a test subject with his Blueprint protocol costing approximately $2 million per year, self-reporting a reversal of biological age by 5.1 years. He leads the "Don't Die" movement, though critics point out this amounts to "case-report level evidence (the lowest tier of scientific evidence)."
Ray Kurzweil predicts that around 2032 humanity will reach a state where "for every year you live, scientific progress restores a year of life expectancy" — known as Longevity Escape Velocity (LEV). Aubrey de Grey (SENS Research Foundation) predicts a 50% probability of reaching LEV by the mid-2030s, while George Church (geneticist, founder of Rejuvenate Bio) anticipates it around 2050.
Japan — Lessons and Opportunities from the World's Most Aged Society
Japan is simultaneously the most important market and the country with the richest insights for longevity tech.
Japan's population aged 65 and over reached 36.19 million people, or 29.4% of the total population, in 2025 — a record high. The number of centenarians reached approximately 100,000 in 2025 (compared to just 153 in 1963). Japan entered the world's first "super-aged society" in 2006 and is expected to maintain its status as the world's oldest society through 2050.
The Okinawa Centenarian Study (OCS), established in 1975, is the world's longest ongoing centenarian study, with over 3,000 participants. As one of the Blue Zones, plant-based diet, moderate portions, natural physical activity, and strong community bonds have been identified as longevity factors. Research suggests that "Ikigai" — a sense of purpose, or "why one gets up in the morning" — can extend life expectancy by up to 7 years. However, rapid Westernization has been eroding Okinawa's longevity advantage.
Shinya Yamanaka's discovery of iPS cells (Nobel Prize winner) forms the foundation of cellular reprogramming, and he also serves as a scientific advisor to Altos Labs. Japan also leads the world in elderly care robotics and is being analyzed by the WEF and Morgan Stanley as a model case for the "longevity economy."
Regulatory Barriers and Breakthroughs——Changes at the FDA
The biggest regulatory barrier for longevity tech is that the FDA does not recognize aging as a disease.
The lack of clinically validated biomarkers that precisely define aging, and the difficulty of designing clinical trials for drugs targeting a slow and complex biological process, stand as key obstacles. Currently, zero geriatric therapeutics have been approved.
However, there are signs of change. The 2025 FDA regulatory update eliminated the requirement for two pivotal trials, making a single trial the default standard. This opens the door for therapeutics based on biomarkers of inflammation, metabolic health, and immune resilience. The THRIVE Act (a regulatory framework for healthspan products) has been proposed in Congress. As evidence of GLP-1's longevity effects accumulates, it may accelerate a regulatory paradigm shift toward "treating aging."
Future Outlook — Will Longevity Escape Velocity Be Achieved?
Industry leaders are optimistic about the future of longevity tech.
Fastest approval candidate: Loyal LOY-002 (for dogs) may reach market in 2026. If approved, it would become the FDA's first lifespan-extending drug and set a regulatory pathway precedent for human therapeutics.
2026–2028: Cellular reprogramming clinical trials accelerate in earnest. Retro Bio, NewLimit, and Turn Bio enter clinical stages in succession. Evidence accumulates on GLP-1's longevity effects, further accelerating entry by major pharmaceutical companies.
2030s: Ray Kurzweil predicts reaching "longevity escape velocity" around 2032 — a state where for every year lived, scientific progress restores one year of lifespan. Aubrey de Grey forecasts a 50% probability by the mid-2030s.
"Longevity Escape Velocity (LEV)" is a concept coined by David Gobel and named by Aubrey de Grey in 2004. If achieved, it would theoretically enable indefinite lifespan extension. Currently still a hypothesis, but with the convergence of AI and biotechnology, optimistic forecasters argue it could be reached as early as the 2030s.
If Dario Amodei's (Anthropic CEO) prediction that "AI will compress 50–100 years of biological progress into 5–10 years" proves correct, longevity tech will become one of the most significant technological innovations in human history.
Impact on the Industry
First, investment in longevity tech has shifted from the "exploration" phase to the "conviction" phase. VC investment of $8.49 billion in 2024 (up 220% year-on-year), Eli Lilly's investment in NewLimit, and GLP-1 clinical data all indicate that major pharmaceutical companies and institutional investors have begun to recognize "treating aging" as a new therapeutic category.
Second, cellular reprogramming accounts for approximately 60% of total longevity VC funding, led by Altos Labs ($3 billion), Retro Biosciences ($5 billion valuation), and NewLimit ($1.62 billion valuation). Nearly 20 years after Yamanaka Shinya's discovery, partial reprogramming is beginning to enter the clinical stage.
Third, data showing a 3.1-year reversal of biological age with GLP-1 agonists (semaglutide) demonstrated the possibility that existing approved drugs could function as de facto "longevity drugs." Even if the FDA does not recognize aging as a disease, a "backdoor" approach may be viable — whereby drugs approved for diabetes and obesity indications deliver longevity benefits.
Fourth, as the world's most aged society, Japan holds both the greatest "need" and the most abundant "knowledge" in longevity tech. A demographic structure of 29.4% aged 65 and over and 100,000 centenarians makes Japan uniquely valuable in the world — both as a market for longevity technology and as a subject of research. The Okinawa studies, the Yamanaka factors, robotic caregiving — Japan has the potential to become a frontrunner in this field.
References: López-Otín et al., "Hallmarks of Aging: An Expanding Universe" (Cell, 2023), Mordor Intelligence Longevity Market Report, Market Research Future Longevity Market, Crunchbase Longevity Startup Funding (2025), Longevity Funding Trends 2022–2026 (NewMarketPitch), Altos Labs Science & Cell Paper (2025), TechCrunch Retro Biosciences $1B Raise (2025/1), Retro Bio First-in-Human Trial, NewLimit Series B & Eli Lilly Investment (2025), BioAge Labs IPO (2024/9), Loyal FDA RXE & TAS Acceptance (2025–2026), STAT News AbbVie-Calico Split (2025/11), Nature Biotechnology "GLP-1s as Longevity Drugs," Semaglutide Biological Age Reversal Study (PRNewswire), Bryan Johnson Blueprint 2026 Update, Unity Biotechnology ASPIRE Trial, Cambrian Biopharma Pipeline, Rejuvenate Bio Gene Therapy Lifespan Extension, Turn Biotechnologies ARMMs Acquisition (2025/3), Hevolution Foundation Grants (Al Arabiya, 2025), Hevolution Global Healthspan Summit 2025, Saudi Vision 2030 Healthspan, Peter Diamandis XPRIZE Healthspan ($101M), Insilico Medicine Phase 2a Results, TruDiagnostic Horvath Clock Analysis, Deep Longevity Aging Clocks, Therapeutic Plasma Exchange (Aging Cell, 2025), Dario Amodei "Machines of Loving Grace" (2024/10), Ray Kurzweil MIT LEV Prediction, Aubrey de Grey LEV Prediction, Japan Elderly Population 2025 (Japan Times), Japan 100,000 Centenarians (FTN News), Okinawa Centenarian Study (JSTAGE), WEF Japan Longevity Economy, FDA Drug Approval Rules Change (Longevity.technology), THRIVE Act, AMA Journal of Ethics Life Extension (2025/12), NAD+ Boosters Clinical Evidence (GetHealthspan), Oliver Wyman Longevity Revolution, Age1 Pharma Aging Report Card 2025